CompletedPhase 2

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Belgium1,108 participants

Plain-language summary

The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months Exclusion Criteria: * Pregnant and breastfeeding women * Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)

Trial details

NCT IDNCT00337090

SponsorAstellas Pharma Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-03

View on ClinicalTrials.gov More Overactive Bladder trials